In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Pharmaceutical

Division of Endo International PLC
www.parpharm.com/generics.php

Latest From Par Pharmaceutical

Momentum Is Back At Cipla In Q2

Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.

Sales & Earnings Companies

Momentum Back At Cipla In Q2 But Albuterol Delayed In US

Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.

Commercial Sales & Earnings

Lupin’s ProAir Rival Has 'Moved Ahead' Despite CRL

Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.

Regulation Generic Drugs

US Setback For Lupin’s GxProAir But Application Has 'Moved Ahead'

Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.

Policy & Regulation India
See All

Company Information

UsernamePublicRestriction

Register